Cartesian Therapeutics (Cartesian Therapeutics) 5-Year Dividend Growth Rate : 0.00% (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Cartesian Therapeutics 5-Year Dividend Growth Rate?

Cartesian Therapeutics's Dividends per Share for the three months ended in Mar. 2024 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Cartesian Therapeutics's Dividend Payout Ratio for the three months ended in Mar. 2024 was 0.00. As of today, Cartesian Therapeutics's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Cartesian Therapeutics's 5-Year Dividend Growth Rate

For the Biotechnology subindustry, Cartesian Therapeutics's 5-Year Dividend Growth Rate, along with its competitors' market caps and 5-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cartesian Therapeutics's 5-Year Dividend Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cartesian Therapeutics's 5-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Cartesian Therapeutics's 5-Year Dividend Growth Rate falls into.

Cartesian Therapeutics 5-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Cartesian Therapeutics (NAS:RNAC) 5-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Cartesian Therapeutics's Dividend Payout Ratio for the quarter that ended in Mar. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Mar. 2024 )	/	EPS without NRI (Q: Mar. 2024 )
	=	0	/	-2.376
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cartesian Therapeutics 5-Year Dividend Growth Rate Related Terms

Thank you for viewing the detailed overview of Cartesian Therapeutics's 5-Year Dividend Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Cartesian Therapeutics (Cartesian Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cartesian Therapeutics Inc (NAS:RNAC) » Definitions » 5-Year Dividend Growth Rate

Comparable Companies

Traded in Other Exchanges

1S7:Germany

Address

65 Grove Street, Watertown, MA, USA, 02472

Website

https://www.selectabio.com

Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. Its product pipeline includes MMA-101, SEL-212 for Chronic Severe Gout, SEL-313 for Ornithine Transcarbamylase Deficiency (OTC), and others.

Executives

Carsten Brunn	director, officer: President & CEO	C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
Peter G Traber	officer: Chief Medical Officer	430 THAMER LANE, HOUSTON TX 77025
Takashi Kei Kishimoto	officer: Chief Scientific Officer	480 ARSENAL ST., BUILDING ONE, WATERTOWN MA 02472
Lloyd P. Johnston	officer: COO and SVP, R&D	480 ARSENAL ST., BUILDING ONE, WATERTOWN MA 02472
Blaine Davis	officer: Chief Financial Officer	C/O ARTARA THERAPEUTICS, INC., 1 LITTLE WEST 12TH STREET, NEW YORK NY 10014
Carrie Smith Cox	director	SCHERING-PLOUGH CORPORATION, 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Timothy C Barabe	director	C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Timothy A Springer	director	36 WOODMAN ROAD, CHESTNUT HILL MA 02467
Kevin Tan	officer: Chief Financial Officer	20 HICKORY ROAD, WELLESLEY MA 02482
Nishan M Desilva	director	11119 NORTH TORREY PINES RD STE 200, LA JOLLA CA 92037
Ann K. Donohue	officer: VP Finance	C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, BUILDING ONE, WATERTOWN MA 02472
Bradford D. Dahms	officer: Chief Financial Officer	C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
Goran Ando	director
Scott Dunseth Myers	director	C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Elona Esq. Kogan	officer: General Counsel	C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065